ReviewCureus2021
Association of Intestinal Microbial Dysbiosis With Chronic Obstructive Pulmonary Disease.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Pooled it
- The effects of various nutritional supplements in patients with chronic obstructive pulmonary disease: a network meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Characterizing gut microbial dysbiosis and exploring the effect of prebiotic fiber supplementation in patients with COPD.European journal of nutrition · 2025Trial
- Microbiome and aging: Trajectories of microbiome age across human ecosystems and their systemic effects.iMeta · 2026Review
- Benefits and mechanisms of polysaccharides derived from traditional Chinese medicine for ulcerative colitis treatment (Review).Experimental and therapeutic medicine · 2026Review
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
- Research Advances on the Impact of Gut Microbiota on COPD: Exploring New Perspectives on the Microbiota-Gut-Lung Axis.Current microbiology · 2025Review
- The Role of Gut Microbiota on Idiopathic Pulmonary Fibrosis Mediated by Circulating Inflammatory Proteins: A Two-Step, Two-Sample Mendelian Randomization Study.The clinical respiratory journal · 2025Article
- Trends in intestinal aging: From underlying mechanisms to therapeutic strategies.Acta pharmaceutica Sinica. B · 2025Review
- Decoding mechanisms and protein markers in lung-brain axis.Respiratory research · 2025Review
- Assessment of upper respiratory and gut bacterial microbiomes during COVID-19 infection in adults: potential aerodigestive transmission.Scientific reports · 2025Article
- The gut and lung microbiome across the TB disease spectrum.Frontiers in microbiology · 2025Review
- Chronic obstructive pulmonary disease: in-depth analysis of microbiota association and innovative prevention and treatment approaches from the gut-lung axis perspective.Frontiers in immunology · 2025Review
- Effects and mechanisms ofWorld journal of gastroenterology · 2024Review
- The potential protective effects of probiotics, prebiotics, or yogurt on chronic obstructive pulmonary disease: Results from NHANES 2007-2012.Food science & nutrition · 2024Article
- Ventilatory pressure parameters impact the association between acute gastrointestinal injury and all-cause mortality in mechanically ventilated patients.Scientific reports · 2024Observational
- Gut microbiota was highly related to the immune status in chronic obstructive pulmonary disease patients.Aging · 2024Article
- Impact of cigarette smoking on gut microbial dysbiosis: a structured literature review.Gut microbiome (Cambridge, England) · 2024Review
- COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens.Frontiers in cellular and infection microbiology · 2024Review
- Air pollution, dysbiosis and diseases: pneumonia, asthma, COPD, lung cancer and irritable bowel syndrome.Future microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Normal gut flora plays various beneficial roles for the human body, including the protection against inflammatory states and mucosal viral infections. It also influences the immune system of the body. The metabolites produced by the gut bacteria control local and other systemic organs' immune functions like the lungs and brain, playing a role in their response to acute and chronic illnesses. Probiotics have shown beneficial effects on lung health. On the contrary, dysbiosis is associated with several diseases, including asthma, chronic bronchitis, emphysema, allergies, and other acute viral infections. By altering the diet of patients with respiratory diseases like patients with chronic obstructive pulmonary diseases (COPD), we may be able to mitigate their conditions. This literature review aims to discuss the mechanisms altering the gastrointestinal flora, the pathophysiology of gut and lung axis, the role of diet in gut microbe health, and the association of COPD with gut dysbiosis and peptic ulcer disease (PUD). We have extracted the data from PubMed and Google Scholar, consisting of review articles, case-control studies, and animal studies. The studies showed an association between gut microbes and different lung diseases. It is found that gut dysbiosis not only disrupts intestinal immunity but may also facilitate the development of COPD. Present studies also show an increased seroprevalence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.